H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Sorrento Therapeutics to $13 from $20 and keeps a Buy rating on the shares. The reduced target accounts for the continuing evolution of the COVID-19 pandemic, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SRNE:
- Sorrento Issues “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock
- Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued an “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock
- Sorrento Therapeutics releases Phase 1b data of OVYDSO
- Sorrento Releases Positive Results from a Phase 1b Study in China in COVID-19 Patients and is Ready for Pivotal Phase 3 trials with OVYDSO™ (STI-1558), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting
- Notable open interest changes for January 6th